Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of death of patients suffering from chronic or acute diseases or conditions

摘要

According to the present disclosure, it has been found that administration of anti-ADM antibody, anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold can significantly reduce the risk of death in patients suffering from severe chronic or acute disease. . In a preferred embodiment of the present disclosure, said anti-ADM antibody, anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM located in the N-terminal portion (aa1-21) of adrenomedullin (see FIG. 2). See In another preferred embodiment, said anti-ADM antibody, anti-ADM fragment or anti-ADM non-Ig scaffold recognizes and binds the N-terminal end (aa1) of adrenomedullin. The N-terminal end means amino acid 1, that is, “Y” in SEQ ID NO: 21 or 23 is essential for antibody binding. The anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold does not bind to the N-terminal extended adrenomedullin, N-terminal modified adrenomedullin, or N-terminally degraded adrenomedullin in the preferred embodiment.